Valuation: Integrity Applications, Inc.

Market Cap 11.25L 10L 9L 9L 16.04L 11Cr 16.26L 1.13Cr 43.78L 5.52Cr 42.25L 41.34L 18Cr P/E 2024 *
-
P/E 2025 -0.12x
Enterprise Value -28.12L -24.97L -23.35L -21.28L -40.07L -27Cr -40.62L -2.83Cr -1.09Cr -14Cr -1.06Cr -1.03Cr -44Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
92.02%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 55 14/07/2026
Director of Finance/CFO 66 28/01/2025
Chief Operating Officer - 01/02/2025
Director TitleAgeSince
Director/Board Member 56 25/08/2023
Chairman 64 13/02/2024
Director/Board Member 78 14/06/2024
Change 5-day change 1-year change 3-year change Capi.($)
+15.79%+10.00% - - 13.09L
+4.16%+3.04%+49.37%+94.17% 7.45TCr
-0.61%+0.81%+27.25%+82.72% 6.01TCr
-2.54%-1.65%+4.86%+31.72% 4.82TCr
-3.02%-5.20%+27.94%+32.51% 4.43TCr
+0.31%+3.02%+348.95%+643.82% 4.4TCr
-1.96%-0.33%+7.04%+99.46% 4.16TCr
+3.32%+3.49%+10.10%+51.23% 3TCr
+4.77%+8.00%+36.77%+22.78% 2.93TCr
-4.86%-10.66%-26.27%+330.06% 2.49TCr
Average +1.54%-0.08%+54.00%+154.28% 4.41TCr
Weighted average by Cap. +0.17%+0.11%+58.36%+145.78%

Financials

2024 2025
Net sales - -
Net income -2.26Cr -2.01Cr -1.88Cr -1.71Cr -3.22Cr -217.57Cr -3.26Cr -23Cr -8.79Cr -110.8Cr -8.48Cr -8.3Cr -355.89Cr -1.94Cr -1.72Cr -1.61Cr -1.47Cr -2.76Cr -186.67Cr -2.8Cr -19Cr -7.54Cr -95Cr -7.28Cr -7.12Cr -305.35Cr
Net Debt -53.5L -47.52L -44.44L -40.5L -76.24L -52Cr -77.29L -5.38Cr -2.08Cr -26Cr -2.01Cr -1.97Cr -84Cr -39.37L -34.97L -32.7L -29.8L -56.1L -38Cr -56.87L -3.96Cr -1.53Cr -19Cr -1.48Cr -1.45Cr -62Cr
Logo Integrity Applications, Inc.
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Employees
-